13F Holdings
中文EN

ONCO Onconetix, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1782107 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-51.3%
TTM net income YoY76.9%
TTM EPS YoY216.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin80.4%
Operating margin-2,525.0%
Net margin-1,578.8%
FCF margin—
EBITDA margin-2,522.7%

Returns

ROE-105.2%
ROA-57.4%
ROIC (approx.)-195.9%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets18.0%
Debt / equity0.00x
Current ratio2.21x
Interest coverage-52.44x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$815,371$2.52M$58,465——
Cost of revenue$182,458$1.47M$1.19M——
Gross profit$632,913$1.06M-$1.13M——
R&D expense—$154,359$1.95M$4.13M$1.33M
SG&A expense$7.04M$11.23M$14.77M$9.35M$2.09M
Operating income-$17.86M-$56.49M-$36.03M-$13.48M-$3.42M
Interest expense$751,005$873,433$671,625——
Pretax income-$14.03M-$59.74M-$37.42M-$13.42M—
Income tax$525-$1.05M-$12,593$3.16T$675.73B
Net income-$14.03M-$58.69M-$37.41M-$13.42M-$3.42M
EBITDA-$17.84M-$55.76M-$35.99M-$13.47M-$3.41M
EPS (basic)-16.56-1,823.39-87.45-1.10-1.26
EPS (diluted)-16.56-1,823.39-87.45-1.10-1.26
Dividends declared per share———1.23—
Weighted avg. shares (diluted)937,69032,301427,78412.27M3.20M
Banking
Deposits—$3.50M$3.50M——
Balance sheet
Cash & equivalents$5.22M$646,500$4.55M$25.75M$1.93M
Receivables$296,866$25,717$149,731——
Inventory$149,961$64,079$364,052——
Current assets$6.07M$950,267$5.84M$26.26M$3.07M
PP&E, net$37,085$62,896$60,654$14,089$11,502
Goodwill$18.55M$18.55M$55.68M——
Intangibles——$25.41M——
Total assets$24.93M$28.18M$87.52M$26.31M$3.08M
Current liabilities$9.14M$18.29M$17.19M$3.92M$1.64M
Total liabilities$9.16M$18.57M$21.88M$3.92M$1.64M
Shareholders' equity$15.76M$8.54M-$5.60M$22.39M$1.45M
Shares outstanding31,198138,270558,09915.27M3.20M
Cash flow statement
Operating cash flow-$9.68M-$10.50M-$13.58M-$8.68M-$2.04M
Capital expenditure—$28,471$3,300$9,339$1,924
Free cash flow—-$10.52M-$13.58M-$8.68M-$2.05M
Investing cash flow—-$28,471-$8.65M-$32,665-$1,924
Financing cash flow$14.45M$6.74M$1.04M$32.53M-$334,188
Depreciation & amortization$15,170$731,345$43,937$6,752$4,890
Stock-based compensation$74,267$438,653$329,760$1.97M$130,141
Share buybacks———$566,810—

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.